Latent and Overt Polyautoimmunity in Children and Adolescents With Immune Thrombocytopenia
Carregando...
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2020
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
KAMIOKA, Priscila E.
MATSUMOTO, Lucy C.
REIS, Joyce M. A.
Citação
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, v.42, n.7, p.E606-E609, 2020
Resumo
Autoantibodies are biomarkers for autoimmune disease diagnosis, monitoring, and prediction. Therefore, this study established the frequency of latent and overt polyautoimmunity in children and adolescents with >6 months of diagnosis of immune thrombocytopenia (ITP). Forty-seven patients with chronic or persistent disease had non-organ-specific and organ-specific autoantibodies assessed. Frequency of latent polyautoimmunity was 36.2%, and, of overt polyautoimmunity, it was 4.3%. Of ITP patients with latent polyautoimmunity, 52.9% were positive for antinuclear antibody (ANA), 47.1% for autoantibodies other than ANA, and 64.7% for multiple autoantibodies. In addition, patients with latent polyautoimmunity and those positive for ANA were significantly older at disease onset. Both ITP patients positive and negative for autoantibodies reported family members with autoimmune diseases. The autoantibodies observed were as follows: ANA, anti-dsDNA, anti-SSA/Ro, IgM aCL, anti-GAD, anti-IA2, anti-IAA, anti-TG, anti-TPO, anti-LKM1, and SMA. Of ITP patients with overt polyautoimmunity, 1 was diagnosed with type 1 diabetes mellitus and the other with thyroiditis. In conclusion, children and adolescents with ITP present high frequency of latent and overt polyautoimmunity even for autoantibodies other than ANA. Therefore, ANA and other non-organ-specific and organ-specific autoantibodies should be considered for assessment during ITP patients' follow-up.
Palavras-chave
autoantibodies, biomarkers, immune thrombocytopenia, polyautoimmunity
Referências
- Abe M, 2011, J GASTROENTEROL, V46, P1136, DOI 10.1007/s00535-011-0421-y
- Aikawa NE, 2012, CLIN EXP RHEUMATOL, V30, P126
- Altintas A, 2008, PLATELETS, V19, P252, DOI 10.1080/09537100801894651
- Altintas A, 2007, J THROMB THROMBOLYS, V24, P163, DOI 10.1007/s11239-007-0031-y
- Anaya JM, 2017, JOINT BONE SPINE, V84, P251, DOI 10.1016/j.jbspin.2016.11.012
- Anaya JM, 2014, AUTOIMMUN REV, V13, P423, DOI 10.1016/j.autrev.2014.01.049
- Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989
- Bay A, 2013, PEDIATR HEMAT ONCOL, V30, P698, DOI 10.3109/08880018.2012.756564
- Culquichicon-Sanchez C, 2016, CUREUS, V8, DOI 10.7759/cureus.512
- Damoiseaux J, 2015, AUTOIMMUN REV, V14, P555, DOI 10.1016/j.autrev.2015.01.017
- de Jesus AA, 2012, REV BRAS REUMATOL, V52, P971
- Hu ZD, 2014, CLIN CHIM ACTA, V437, P14, DOI 10.1016/j.cca.2014.06.015
- Ito A, 2017, INTERNAL MED, V56, P143, DOI 10.2169/internalmedicine.56.7506
- Jesus Adriana Almeida de, 2007, Rev. Bras. Reumatol., V47, P418, DOI 10.1590/S0482-50042007000600005
- Kim Jochebed Kyoung, 2007, Rev. Bras. Reumatol., V47, P10, DOI 10.1590/S0482-50042007000100004
- Liu Y, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005565
- Pratt EL, 2005, AM J HEMATOL, V79, P175, DOI 10.1002/ajh.20299
- Rodeghiero F, 2009, BLOOD, V113, P2386, DOI 10.1182/blood-2008-07-162503
- Sosenko JM, 2013, DIABETES CARE, V36, P2615, DOI 10.2337/dc13-0425
- Swinkels M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00880
- Tschudin LV, 2015, PEDIATR DIABETES, V16, P138, DOI 10.1111/pedi.12128
- Zhang W, 2010, AUTOIMMUNITY, V43, P682, DOI 10.3109/08916934.2010.506207
- Zimmerman SA, 1997, J PEDIAT HEMATOL ONC, V19, P297, DOI 10.1097/00043426-199707000-00006